CPHI & PMEC India 2023 commenced on Nov 28 at the India Expo Centre in Greater Noida, Delhi-NCR. The Expo provides an unparalleled platform for stakeholders to participate in extensive dialogues covering pharma machinery, packaging, analytical instruments, laboratory technologies, equipment, ancillaries, ingredients, and beyond.

The grand inauguration ceremony was marked by the presence of key dignitaries Dr Veeramani S.V, Vice-Chairman PHARMEXCIL; Harish Jain, President FOPE; Raja Bhanu, Executive Director PHARMEXCIL, Margaret Ma, President & CEO – Informa Markets Asia; Chris Eve, Executive. Vice President – Informa Markets Asia; Adam Anderson, Executive Vice President – Pharma, Informa Markets and Yogesh Mudras, Managing Director, Informa Markets in India.

Highlighting the robust growth of the Indian pharmaceutical industry, Dr S.V. said, “The Indian pharma industry is on a compelling growth trajectory, evidenced by an 8 per cent year-to-date increase in exports and a remarkable 29 per cent surge in October alone. This growth is propelled by expanding market opportunities, heightened demand in the USA, and critical shortages of medicines in the US and Europe. Despite challenges in CIS countries, the global reception of Indian pharma remains positive. The domestic market has exhibited impressive growth, exceeding 10 per cent. Driven by this momentum, I am confident in reaching the 130 billion mark by 2030, advocating for a consistent 10 per cent growth in both domestic and export markets. Expos like CPHI & PMEC India are instrumental in propelling our industry forward, fostering innovation, and reinforcing India’s position on the global pharma stage.”

Sharing insights on the forward-looking stance Anil Matai, Director General, OPPI said, “While discussions revolve around India’s pharma landscape in 2030, our industry is visionary, setting its sights on India in 2047. Aligned with Prime Minister Narendra Modi’s concept of Amrit Kal, we anticipate a trajectory of sustained growth. Exceeding the projected $130 billion mark, the Department of Pharmaceuticals (DOP) envisions an ambitious $200 billion goal.

Achieving this necessitates regulatory reforms to foster industry growth, address patient needs, and promote disruptive innovation, as we learned from the pandemic. Regarding the pharmaceutical sector’s outlook, we foresee stable double-digit growth, around 13-14 per cent, conditional on consistent policies that streamline doing business. CPHI serves as a crucial platform to deliberate on achievements, challenges, and influence regulators for favourable business conditions.”

Addressing the opportunities in this sector, Mudras said, “India’s pharma prowess, contributing a formidable 20 per cent to global exports, achieved a remarkable USD 25.3 billion (Rs 2.1 lakh crores) in the 2022–2023 fiscal year. Robust R&D investments from both domestic and international players drive innovation, a pivotal force propelling market expansion. With government backing, exemplified by Rs 5,000 crores in R&D incentives, India emerges as a key leader in global healthcare development. The CPHI & PMEC India Expo, along with ancillary events during the India Pharma Week, stands as a premier global platform, fostering connections and collaborations within the pharma community. This year, hosting the largest-ever expo edition, it symbolises India’s ascent as a monumental pharma superpower.”